What it is
FOXO4-DRI is a senolytic peptide designed to disrupt FOXO4-p53 signaling in senescent cells. The idea is preclinical; human protocol data are not established.
Evidence boundary
Preclinical / speculative. Do not present a human dosing schedule as established fact.
Trial evidence
No verified human trial found.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–4 (titration) | 250 mcg | 5 U (0.05 mL) | Once daily | 1.75 mg/week |
| Weeks 5–8 | 375 mcg | 7.5 U (0.075 mL) | Once daily | 2.625 mg/week |
| Weeks 9–16 (target) | 500 mcg | 10 U (0.1 mL) | Once daily | 3.5 mg/week |
Weeks 1–4 (titration)
- Dose
- 250 mcg
- Draw / measure
- 5 U (0.05 mL)
- Frequency
- Once daily
- Weekly total
- 1.75 mg/week
Weeks 5–8
- Dose
- 375 mcg
- Draw / measure
- 7.5 U (0.075 mL)
- Frequency
- Once daily
- Weekly total
- 2.625 mg/week
Weeks 9–16 (target)
- Dose
- 500 mcg
- Draw / measure
- 10 U (0.1 mL)
- Frequency
- Once daily
- Weekly total
- 3.5 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Daily titration (subcutaneous):
-
Weeks 1–4 (titration): 250 mcg/day.
-
Weeks 5–8: 375 mcg/day.
-
Weeks 9–16 (target): 500 mcg/day. Upper end of preclinical-derived range.
-
Cycle structure: 12–16 weeks active, then 8–12 week break. An alternative schedule runs 1–2 cycles per year.
-
Whether a source is actually human data
-
Limited safety information
-
Injection-site reactions
-
Theoretical concerns with rapid senescent-cell clearance
Practical rules
- Do not frame preclinical mouse findings as human guidance.
- Rotate sites.
- Pair any longevity work with established basics, not protocol hype.